Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma

References

• European Medicine Agency. Yondelis. European public assessment report. [cited 2020 sep 21]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis
   Google Scholar
• Demetri G, Chawla S, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188–4196.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko J, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480–1490.
   PubMed Web of Science ®Google Scholar
• Yovine A, Riofrio M, Blay J, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22:890–899.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay J, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European organisation for the research and treatment of cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23::576–584.
   PubMed Web of Science ®Google Scholar
• Demetri G, von Mehren M, Jones R, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34:786–793.
   PubMed Web of Science ®Google Scholar
• Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015;16:406–416.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay J, Cupissol D, et al. Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): a French Sarcoma Group (FSG) trial. J Clin Oncol. 2018;36:11508.
   Web of Science ®Google Scholar
• Le Cesne A, Blay J, Domont J, et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol. 2015;16:312–319.
   PubMed Web of Science ®Google Scholar
• Barnish M, Turner S. The value of pragmatic and observational studies in health care and public health. Pragmat Obs Res. 2017;8:49–55.
   PubMed Web of Science ®Google Scholar
• Eichler H, Abadie E, Breckenridge A, et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10:495–506.
   PubMed Web of Science ®Google Scholar
• Blay J, Italiano A, Ray-Coquard I, et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer. 2013;13:64.
   PubMed Web of Science ®Google Scholar
• Samuels B, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013;24:1703–1709.
   PubMed Web of Science ®Google Scholar
• Ploner F, Lamm W, Schur S, et al. The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS). J Cancer Res Clin Oncol. 2013;139:1337–1342.
   PubMed Web of Science ®Google Scholar
• Gounaris I, Hatcher H, Davidson D, et al. Trabectedin for advanced soft tissue sarcomas: a single institution experience. Future Oncol. 2014;10:1843–1851.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Ray-Coquard I, Duffaud F, et al. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur J Cancer. 2015;51:742–750.
   PubMed Web of Science ®Google Scholar
• De Sanctis R, Marrari A, Marchetti S, et al. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. Drug Des Devel Ther. 2015;9:5785–5791.
   PubMed Web of Science ®Google Scholar
• Buonadonna A, Benson C, Casanova J, et al. A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. Anticancer Drugs. 2017;28:1157–1165.
   PubMed Web of Science ®Google Scholar
• Shamai S, Merimsky O. Trabectedin for advanced soft tissue sarcoma: ten year real-world perspective. Isr Med Assoc J. 2018;20:599–603.
   PubMed Web of Science ®Google Scholar
• Davis E, Schuetze S, Patel S, et al. Efficacy and safety of patients treated long-term with trabectedin (t) on the expanded access program: a retrospective analysis. Ann Oncol. 2017;28:529.
   Google Scholar
• Penel N, Buonadonna A, Benson C, et al. A non-interventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma (STS): the first interim analysis of Y-IMAGE study. Eur J Cancer. 2015;51:699.
   Web of Science ®Google Scholar
• Mazzeo F, Blay J, Toulmonde M, et al. Efficacy and safety of trabectedin as an early treatment for advanced STS: an interim analysis of a non-interventional, prospective phase IV study. Connective tissue oncology society, 20th annual meeting; 2015 November 4–7; Utah. Abstract no. 105.
   Google Scholar
• Blay JY, Casali P, Nieto A, et al. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. Future Oncol. 2014;10(1):59–68.
   PubMed Web of Science ®Google Scholar
• Martín-Broto J. Case 2. Cancer Chemother Rev. 2018;13:11–15.
   Google Scholar
• Konstantinos E, Christos A, Chrysanthi K, et al. Complete response after long-term 2nd line treatment with trabectedin in a hemodialyzed patient with metastatic high-grade ovarian sarcoma, case report and short review. Arch Clin Med Case Rep. 2019;3:591–599.
   Google Scholar
• Cordeiro M, Casanova JM, Rodrigues J, et al. Long-term response after 94 cycles of trabectedin in a patient with metastatic leiomyosarcoma of the lower extremity. Case Rep Oncol. 2020;13:113–119.
   PubMed Web of Science ®Google Scholar
• Buonadonna A, Kasper B, Blay J, et al. Trabectedin in elderly patients with recurrent soft tissue sarcoma (STS): an interim analysis of a non-interventional, prospective phase IV study. Connective tissue oncology society, 20th annual meeting; 2015 November 4–7; Utah. Abstract no. 117.
   Google Scholar
• Jones R, Demetri G, Schuetze S, et al. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018;29:1995–2002.
   PubMed Web of Science ®Google Scholar
• Cesne A, Judson I, Maki R, et al. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer. 2013;109:1717–1724.
   PubMed Web of Science ®Google Scholar
• Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117:1049–1054.
   PubMed Web of Science ®Google Scholar
• Le Cesne A. Making the best of available options for optimal sarcoma treatment. Oncology. 2018;95:11–20.
   PubMed Web of Science ®Google Scholar
• Italiano A, Khalifa E, Laizet Y, et al. Genetic landscape of soft-tissue sarcomas: moving toward personalized medicine. J Clin Oncol. 2017;35:11002.
   Web of Science ®Google Scholar
• Fletcher CDM, Bridge JA, Hogendoorn P, et al. WHO classification of tumours of soft tissue and bone (IARC WHO classification of tumours). 4th ed. Lyon: IARC Press; 2013.
   Google Scholar
• Hoang NT, Acevedo LA, Mann MJ, et al. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. J Cancer Manage Res. 2018;10:1089–1114.
   PubMed Web of Science ®Google Scholar
• Blay JY. Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality? Future Oncol. 2019;15:5–10.
   PubMed Web of Science ®Google Scholar
• Reichardt P. Current questions in soft tissue sarcoma: further steps with Yondelis®. Expert Rev Anticancer Ther. 2013;13:25–30.
   PubMed Web of Science ®Google Scholar
• Martin-Broto J, Hindi N, Moura DS. Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma? Future Oncol. 2019;15:17–23.
   PubMed Web of Science ®Google Scholar
• Martin-Broto J, Hindi N, Cruz J, et al. Relevance of reference centers in sarcoma care and quality item evaluation: results from the prospective registry of the Spanish group for research in sarcoma (GEIS). Oncologist. 2019;24:338–346.
   PubMed Web of Science ®Google Scholar
• Dangoor A, Seddon B, Gerrand C, et al. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6:20.
   PubMed Web of Science ®Google Scholar